Meloxicam dose titration study for chronic osteoarthritis in dogs

NCSU Comparative Pain Research Laboratory is performing a clinical investigation using oral meloxicam for dogs with chronic osteoarthritis pain.

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) approved by the FDA for the alleviation of osteoarthritis pain in dogs. Meloxicam and other NSAIDs are one of the most widely used classes of drugs in veterinary medicine.

The aim of this study is to demonstrate that dose reduction can be performed using oral meloxicam, with efficacy maintained and presumably, a lower incidence of adverse effects. It will also demonstrate how much of a dose reduction can be performed before an acceptable level of efficacy is lost.

This is a 12-week, prospective, randomly controlled, blinded study. We are looking for dogs with fore-limb and/or hind-limb lameness and radiographic evidence of osteoarthritis. Other criteria and benefits to the pet owner include:

Requirements:
- Fore-limb and/or hind-limb x-rays confirming osteoarthritis within the last six months (we can repeat or take these if needed)
- No clinically significant blood cell or biochemical abnormalities
- No urinary abnormalities
- No long acting corticosteroids within 8 weeks of entering the study

Benefits:
- Complete orthopedic evaluation by Board Certified Surgeon
- Complete blood counts free of charge
- Complete biochemical profile and urinalysis free of charge
- Survey x-rays (if required) free of charge
- Analgesia medication (approved for use in dogs) for 84 days free of charge
- Helping other dogs live more comfortably with osteoarthritis

If you have any clients with dogs that would benefit from participating in this study or if you are an owner with a dog that may fit this study, please contact us:

Ben Wernham, BVSc
Research Associate
Phone: 919 513 6383
Email: bwernha@ncsu.edu

Duncan Lascelles, BVSc, PhD, DECVS, DACVS
Associate Professor of Small Animal Surgery
Phone: 919 513 6588
duncan_lascelles@ncsu.edu